Brian. in which Pharmaceutical operational by second and Prescription quarter Technology reflect Solutions quarter execution our and of We're results, segments. growth with you, driven solid U.S. pleased performance, Thank our meaningful another
the GAAP to trade quarter impacted highlight of receivable fiscal for GAAP-only We sales recognized bankruptcy. turn million to XXXX that receivable bad Aid I related a for I pretax anticipate Aid's the provision to segment an debt $XXX from Pharmaceutical Rite Before to $XXX results. second bankruptcy within provision for to after trade U.S. quarter tax accounts in bad results, recording its XXXX want third in petition. prior million recorded our October additional $XXX of of or that debt McKesson for consolidated X our item uncollected million Rite We accounts
their the reorganize. efficiency reduced an provide as for providing and continues services, interim over other to to We're years. agreement is excellence post pursuant pending includes to days court we operating bankruptcy Rite Rite services as Aid terms continue credit operational filing, approval, which XX Aid and items and distribution have distribution of We certain for final to same X
monitoring are position material liquidity per and results, and we will share anticipate We not our closely ongoing have fiscal operations. a event customer developments, diluted to business adjusted XXXX this earnings impact
my otherwise. The state results, remainder to comments I our adjusted of XXXX fiscal unless refer
our Solutions of delivered review with Let in segments. quarter U.S. Pharmaceutical a quarter, growth and Prescription second strong by performance me led in results. second solid the start McKesson Technology
solid Our company services. to focused oncology investments evolve consistent, continuing in to diversified our execution and biopharma position results while us grow through our priorities portfolio strategic and focus generate against financial and
$XX.XX. to and outlook year share for narrowing full a year, fiscal of are we a of our range adjusted of to As for $XX.XX and per the operating fiscal remainder XXXX our diluted the result outlook performance earnings increasing
Moving results. by customers, consolidated and to $XX.X prescription GLP-X growth Pharmaceutical segment higher the European partially medication, products for [ offset volumes resulting in of led testing XXXX fiscal specialty XX% businesses. lower from ] to from Revenues by national U.S. including our resulting in the increased International divestitures revenues the segment certain increased billion, account volumes, retail
European Excluding the revenue impact of XX%. increased and our completed business operations divestitures,
to of $X with And related expenses completed profit increased divestitures, the second quarter, of decreased excluding decrease Research profit Solutions Sarah year-over-year, X% Pharmaceutical the XXXX completed operating the acquisitions the a which venture Technology growth in half impact impact Rx Gross And primarily business Cannon Prescription billion segments. Solutions a our quarter our and included fiscal the X%. gross Operating expenses operations, when X%, quarter. Savings the divestitures, and was European excluding Institute. increased European second result approximately from joint and X% for business X% of including U.S. of costs operations of in
the our segment, increased operating the investments with offset divestitures fiscal When Prescription operating equity X% the in in testing U.S. profit in growth our of impact fiscal associated profit primarily including McKesson illness in by within and slower Technology XX% to XXXX, Solutions This Solutions billion, XXXX driven COVID-XX-related by was segment. losses season lower completed and increased quarter Second XXXX business of of Pharmaceutical quarter. International and growth European the segments. $X.X again, our operations Ventures and partially excluding Medical-Surgical items
discrete line. Moving effective tax $XX net a million. below tax included which The was expense rate XX.X%, the of the recognition of
earnings shares quarter second represents million, increase year-over-year. an weighted X% were quarter diluted prior which share XXX.X Second over the diluted year. X% average Consolidated of was of decrease $X.XX, a per outstanding
and share Excluding losses second COVID-XX-related Ventures items the XXXX XXXX, during XXXX portfolio fiscal fiscal McKesson and of over quarter second was earnings XX% the quarter our per within up year. prior in diluted
starting be through U.S. Pharmaceutical found in XX results, our which segment and can strong to profit and continued on quarter operating Turning Slides second growth. delivered X Pharmaceutical. segment The U.S. momentum
distribution this of our segment growth our new expand and to approach our investments and will Our our that drive managing efficiency making to bolstering few balanced movements investment that and new customers factors: in to position operations, product the products, launches further our the sustainable inclusive proposition to we're capabilities a partners, scaled a [ generic nimble pharmaceutical a broad ClarusONE reflects and expansion a unlock sourcing for ] ability in of customer strengthen platform. demand, value portfolio of continued enabling approach in our on market and operations, broad oncology competitive
Research in oncology Institute and pleased expectations. results across our These revenue with the expanded the quarter are We insights our exceeded trial provider venture. operating through in to data oncology and momentum which from the clinical capabilities solutions assets US contributed joint Ontada growth through profit Cannon assets network, Sarah and our
an revenues revenue national were a and year-over-year. volumes These branded-to-generic customers, higher growth an provided in billion, The GLP-X increases increase quarter partially tailwind of products quarter. prescription Revenue increased specialty the of growth volumes, account conversions. offset XX% medications from $XX.X by Second GLP-X were including reflects retail medications.
Pharmaceutical margin a for in medications As distribution U.S. the GLP-X of rates recognize generally we lower the reminder, segment.
In our like access GLP-X uterine has ] increased led [ for launches, to segment, prior the solutions authorization growth Prescription Solutions as of services. our such brand Technology demand medications,
When products delivered fiscal impact operating our quarter excluding growth segment X% in U.S. of million, to of programs. distribution XX% Second contributions the and the the growth distribution Pharmaceutical the of profit increased COVID-XX from driven XXXX, U.S. quarter profit increased generic in vaccine Pharmaceutical specialty $XXX second of by operating year-over-year.
years. partnerships capture demonstrate results of in utilization Moving with strong our to the strength GLP-X differentiated McKesson second the the biopharma driven The to developed The growth the position quarter over trends, and we've Prescription Technology portfolio medications. that by including of our Solutions. manufacturers product partnership and prescription success of demand the strong capabilities
$XXX the second revenues increased operating billion, profit XX% quarter, and million. to XX% For to year-over-year $X.X increased
year-over-year operating increased quarter authorization increased customer business. timing to headcount Second primarily second related higher our our verification in of services to results logistics and XXXX, fiscal growth from activities. the The demand growth which third-party which prescription reflect for quarter prior access support annual of also in higher drove expenses solutions transaction resulted volumes, the included
flat The When profit ancillary lower and million the sales in of In in supplies Medical-Surgical program. of COVID-XX offset from the Solutions, for anticipated ] the business. decrease revenues sales of lower care and the COVID-XX supplies distribution lower prior of were the anticipated year, in growth caging of was of Operating driven $X.X from tests by anticipated XXXX, were quarter [ growth X%, of store items lower COVID-XX-related from resulting and distribution a U.S. U.S. million, was quarter, business. in driven care COVID-XX tests. distribution from lower and COVID-XX nutritional of impact increased in of ancillary by pharmaceuticals program vaccine extended $XXX government's the primary the which fiscal [ increased delivered XX%, to segment revenues operating contribution storage by business caging the COVID-XX-related volumes in contributions extended government's partially and profit care vaccine ], excluding the second supplements the
testing quarter illness to market start market rate second moderated the growth to slower prior which The including exhibited market Solutions when volumes. compared second season indications, related Medical-Surgical quarter the IQVIA on the to illness and partially these other a Based indications, primary season, was year. care reflects
profit a the was were decrease address billion, XX% $X.X XX%. me of million, And results. $XX of Revenues International a year-over-year. quarter Next, decrease in second let operating our
divestitures of corporate quarter, of results were European our the review, the year-over-year $XXX business. expenses wrapping our In completed quarter reflect Second effects the up an within year-over-year. XX% segment in increase million
compared McKesson to During XXXX. $XX Ventures share of the the or within quarter related the fiscal portfolio equity approximately of second $X.XX had we losses $X quarter, million million of investments per losses in to
a pleased the performance or insights health portfolio. the Ventures we the the As companies. through can digital on portfolio quarter-to-quarter. and may investment. are obtaining with results We're The in and timing equity investments McKesson the services influenced impacts gains And growth-stage financials a this holds reminder, in several be of investments vary magnitude of losses, as consolidated each by result, investment individual result for McKesson's which each and can that
XX cash ended million Turning can cash now XX. with Slide the billion to We in flows found $X.X cash the on second for flow billion of and cash $XXX which quarter trailing the capital We deployment, equivalents. delivered in months. and free be $X.X and quarter
Our in million payments for quarter totaling cash opioid-related balance agreements with included second $XXX settlement cash associated flow and free the claims.
our on, working vary metrics which impacted day from flows the includes can As position, be of the quarter-to-quarter. and the and a cash resulting week capital timing, each reminder, that by can cash ends therefore, quarter
of fiscal centers $XXX and $XXX dividend included investments and first the capital data and Year-to-date, repurchases the billion $X.X in made our to we payments. of well to During year, investments returned million of priorities. shareholders, $X.X included support million distribution which of which as expenditures, X share existing billion new growth in analytics in technology, we cash months
Now let updated me our outlook. discuss
basis. we a in on on found can supplemental presentation. XXXX. GAAP forward-looking I'm to provide metrics [indiscernible] The today XX a on are relates guidance guidance provided following XX be As assumptions The our adjusted basis. not reminder, Slides providing our do fiscal non-GAAP slide through an
for the with outlook start our segments. me Let
profit to we and year-over-year. to year, XX% operating X% X% the revenues For now XX% to full Pharmaceutical increase anticipate increase U.S.
outlook XX% well to as increase in quarter programs the anticipate our vaccine the specialty XX%. profit distribution, including growth fiscal This distribution COVID-XX differentiated sourcing biologics of generic further in plasma and impact we as and second our business. segment updated strong to incorporates operating Excluding performance XXXX,
Our anticipate in vary outlook fourth medications fiscal compared compared quarter, We of reflecting volumes consolidated that full medication elevated inflection medications quarter the GLP-X may to fiscal will to volumes the assumes slow GLP-X prior profit our related for and remain fourth in the revenue year XXXX. to growth in operating will quarter-to-quarter. prior year year and these the
anticipate tailwind to Pharmaceutical. a for be will U.S. GLP-X revenue medications We continue
X% However, headwind anticipate a represents profile distribution to the has In lower and XX%. Prescription segment, distribution growth medications a results. of Solutions we Technology margin to year of prior rate these revenue
timing, operating increased reflecting profit We performance. in our segment, first may Access quarter-to-quarter to expand the pace customers and have and and and outlook our our verification trajectory programs variability and the to this investments strong our in new half fiscal Solutions of drug that to We our momentum transaction launches, and quarter. fourth size we XX%, product timing in product provide XX% strong portfolio occur support growth prescription to to driven continue for volumes, the annual that by see
remains positioned the XX%. alternate profit growth segment X% In anticipate across assortment decline to to all and revenues Solutions channels decrease capabilities. be scale, to Solutions X% Our to with a approximately product Medical-Surgical and operating XX% well Medical-Surgical site we unmatched segment,
volumes the fiscal COVID-XX tests will year, to COVID-XX-related continue remain items fiscal we of from the full to For XXXX XXXX. anticipate impact results. compared And to decline to immaterial
to results, COVID-XX-related year-over-year. increase from the we impact fiscal operating Excluding to of X% items X% XXXX profit anticipate
XXXX. by traffic, modest the quarter earlier. remainder market Our may season, in of second the persist primary outlook I illness moderations through care We foot which a driven in anticipate results incorporates part fiscal discussed general the
results from half an season, illness benefited XXXX. fiscal in Additionally, fiscal repeat which did XXXX not extended first
breadth network non-acute and physician offices. our investments state-of-the-art distribution, base. capabilities our chain the and serve scaled distribution to of automation cold of support COVID customer the for broader These customers for continued vaccines example, network, regulatory includes investments our outlook distribution adding Our in breadth
in We the reach and analytics anticipate data brand and for product private channel our further to pharmaceuticals also investments medical supplies, expand portfolio.
to million the Ventures and profit a first segment, to to be losses our the European to range closed International equity the of of the investment we of XX% we year-over-year to In million, anticipate anticipate operating loss in the to during with $XXX McKesson we in decline segment, XX% from which decrease that Corporate by growth contribution by and recorded XXXX. and half $XXX elevated businesses. year expenses businesses fiscal includes spend transactions operating profit to in XX%. revenues Finally, includes technology This XX% associated support of the decline
anticipate and discrete guidance. XX% items be line, approximately below we timing to therefore, full tax to Moving of effective XX%. to quarterly the predict, do the not is effective The rate difficult year provide tax we typically tax rate
However, our in discrete a quarter. tax fiscal our outlook includes third of benefit recognition
As reflecting And $XXX the we lower finally, anticipate quarter. income quarter we sourcing fourth third million, be range million the the to a in ClarusONE's to to compared rate to ] $XXX as now attributable anticipate of to tax interest noncontrolling be result, generic success. [
capital anticipate deployment. We cash to $X.X Turning approximately $X.X cash and to billion free flow flow billion. of
Our plans approximately outlook to billion repurchase $X.X shares. incorporates of
weighted shares of to outstanding result range diluted a activity, average million. repurchase the of As estimate share we in XXX approximately the be
increase remainder as the new of to year. outlook a year-over-year. of are anticipate range outlook narrowing We diluted we year, per we $XX.XX profit profit our share the earnings increasing X% prior solid to a performance with for to $XX.XX. excluding flat result fiscal by XX% and to summary, in combined anticipate fiscal XXXX, operating second the of the In compared X% for quarter will items, of certain to operating decline our fiscal When be XXXX
XXXX fiscal Healthcare XXXX; Medical-Surgical will comparing U.S. in related COVID-XX-related a to As benefit in agreement COVID-XX-related and XXXX; receivable XXXX. XXXX. $X.XX and fiscal Pharmaceutical the related Change in with in following: gains segment We a equity the XXXX be include tax anticipate associated in certain items reminder, $X.XX termination when fiscal fiscal losses the impact early to items and net immaterial items investments and McKesson the of fiscal Ventures with of our
diluted for excluding to indicates the earnings European when for the outlook of from XX% diluted growth share per XX% year. XX% to runoff to operations, increase When further indicated at per growth share The of full XX% the per adjusted contribution our earnings earnings is share diluted excluding items. these our certain
of be than We fiscal third visits, the the the the patient discrete third to recognition quarter benefit on development anticipate fiscal transactions, fourth quarter based quarter. a prescription in and tax investments also the of stronger internal
closing, momentum customers business, in us positions The with sustainable strong our biopharma our And shareholder we and including deliver that, across to our In let's are performance. our and partners and to first platforms, for growth to pleased the the oncology move half with services create Q&A. value.
